Hackensack University Medical Center in New Jersey, renowned for its pioneering advancements in cardiology, has become the first medical center in the state to introduce a revolutionary diagnostic tool for microvascular disease. The Coroventis CoroFlow Cardiovascular System, employed by interventional cardiologists, is transforming the assessment of smaller arteries in the heart and enabling accurate diagnoses of cardiac small vessel disease, a condition that has long posed diagnostic challenges.
Microvascular disease, which affects the inner lining and walls of tiny blood vessels branching off the coronary arteries, often presents with symptoms like chest pain, shortness of breath, and fatigue. Unlike atherosclerotic plaque in major coronary arteries, this condition is difficult to visualize during cardiac catheterization. However, the CoroFlow system, in conjunction with Abbott’s PressureWire X Guidewire, offers a wireless solution that generates crucial hemodynamic data, providing comprehensive insights into the heart’s function.
Dr. Ankitkumar Patel, an interventional cardiologist at Hackensack University Medical Center, describes the CoroFlow Cardiovascular System as a “revolutionary diagnostic tool” exclusive to a select number of heart centers across the United States. Since its introduction in March, over 50 cases have been successfully evaluated using the system. Dr. Patel emphasizes its ability to accurately diagnose microvascular disease caused by invisible blockages in the heart’s smallest arteries, enabling personalized treatment plans for patients.
One of the primary advantages of the CoroFlow system is its role in relieving patients of the uncertainty associated with undiagnosed chest pain. Patients often find themselves seeking multiple medical opinions and undergoing repetitive diagnostic tests. With the CoroFlow system, patients leave the catheterization lab with a definitive answer regarding the presence or absence of microvascular disease, providing them with a tangible condition to address.
Dr. Patel’s team at Hackensack University Medical Center has already utilized the CoroFlow system to match patients with effective therapies or refer them for further testing when microvascular disease is ruled out. This groundbreaking technology has empowered physicians to alleviate patients’ discomfort, improve their quality of life, and enhance heart health.
The significance of this diagnostic breakthrough extends beyond patient care. The introduction of the CoroFlow system enables further research and advancements in the understanding and treatment of microvascular disease. Hackensack University Medical Center’s commitment to utilizing cutting-edge techniques positions it as a frontrunner in the field of cardiology, ensuring the delivery of exceptional heart care to individuals in New Jersey and the surrounding areas.
As the medical community continues to explore the potential of the CoroFlow Cardiovascular System, Hackensack University Medical Center’s dedication to innovation propels them to the forefront of cardiology. Patients can now rely on this state-of-the-art technology to receive comprehensive diagnoses and tailored treatment plans, eliminating the uncertainty that often accompanies heart-related complaints. Discover how Hackensack istransforming heart care with the revolutionary Coroventis CoroFlow Cardiovascular System, an innovative diagnostic tool for microvascular disease. This wireless device, used in conjunction with Abbott’s PressureWire X Guidewire, enables accurate assessment and diagnosis of cardiac small vessel disease, providing patients with answers and effective treatment options. Hackensack University Medical Center’s commitment to advanced techniques and personalized care establishes it as a leader in cardiology, benefiting patients throughout New Jersey and beyond.
